Advance in integrating platinum-based chemotherapy with radiotherapy for locally advanced nasopharyngeal carcinoma

Frontiers in Oncology

Oncology

Yidan Wu¹  Fubin Zhu²  Hua Wang³ 

[1] Center for Geriatric Medicine Assessment and Treatment, The Fourth People's Hospital of Chengdu, Chengdu, China;Department of Cancer Center, Chengdu Seventh People's Hospital (Affiliated Cancer Hospital of Chengdu Medical College), Chengdu, China;Department of General Surgery, Chengdu Public Health Clinical Medical Center, Sichuan, Chengdu, China;

关键词: nasopharyngeal carcinoma;    concurrent chemoradiotherapy;    chemotherapy;    Platinum;    Cisplatin;   

DOI  :  10.3389/fonc.2023.1259331

 received in 2023-07-15, accepted in 2023-09-12,  发布年份 2023

来源: Frontiers

【 摘 要 】

Nasopharyngeal carcinoma (NPC) is a malignant tumor characterized by the malignant transformation of nasopharyngeal epithelial cells. It is highly sensitive to radiation therapy, making radiotherapy the primary treatment modality. However, 60-80% of patients are initially diagnosed with locally advanced NPC (LA-NPC), where radiotherapy alone often fails to achieve desirable outcomes. Therefore, combining radiotherapy with chemotherapy has emerged as an effective strategy to optimize treatment for LA-NPC patients. Among the various chemotherapy regimens, concurrent chemoradiotherapy (CCRT) using platinum-based drugs has been established as the most commonly utilized approach for LA-NPC patients. The extensive utilization of platinum drugs in clinical settings underscores their therapeutic potential and emphasizes ongoing efforts in the development of novel platinum-based complexes for anticancer therapy. The aim of this review is to elucidate the remarkable advances made in the field of platinum-based therapies for nasopharyngeal carcinoma, emphasizing their transformative impact on patient prognosis.

【 授权许可】

Unknown   
Copyright © 2023 Zhu, Wu and Wang